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Abstract:  
Cancer is a lethal disease and is one of the leading causes of death in the world. Though there 
have been enormous leaps in the field of cancer treatment and prolonged patient survival rate, 
new therapies are still in high demand. Cancer immunotherapy is an emerging field in cancer 
treatment especially for patients with late stage cancers that had few options previously. Cancer 
immunotherapy is composed of CAR-T cell therapy, immune checkpoint inhibitors (ICI), and 
cancer vaccines. ICIs are monoclonal antibodies, which are used to block certain immune 
checkpoint from binding with tumor cells, preventing the shutdown of the T-cell. As of now, 
there have been 6 ICIs approved for many different cancer indications that target the proteins, 
PD-1, PD-L1 and CTLA-4 that have significantly increased patient response rates in recent 
years. In this review, the concept, history, recent advances in ICIs, and existing commercial 
drugs and their response rates in different cancer indications were summarized; the advantages 
and disadvantages of ICI treatment in cancer were also discussed.  
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1. Introduction 
Cancer is a collection of related diseases in which the body’s cells have mutated and grow 
abnormally that can invade and spread to the rest of the body. It is a leading cause of death with an 
estimated amount of 1.76 million new cases and 606,880 deaths in 2019 [1]. Cancer can be broken down 
into four major types which are carcinomas, sarcomas, leukemias, and lymphomas [2]. There are many 
treatments for cancer. The early treatments for cancer involved fancy medicines such as fox lungs and 
ground white coral or barber-surgeons performing mastectomies without anesthetics in extremely 
unsanitary conditions. Later on with the discovery of general anesthetics, surgeons were able to perform 
radical surgery ensuring the removal of the tumor, but uncertain if they had truly cured the patient. In 
1896, Emil Grubbe pioneered the usage of x-rays and other forms of radiation to kill the tumors. Grubbe 
did not understand why radiotherapy worked, but now we know that radiation broke the DNA that 
controlled cell division killing both healthy and cancer cells. During the 1940s, anticancer drugs made 
their appearance, the first of which was nitrogen mustard and rechristened mustine which were the first 
chemotherapy licensed agent. The principles of chemotherapy are that it can seek cancer cells out 
regardless of their location in the body even if it had spread. Now immune checkpoint inhibitors(ICI) 
have taken over the market of cancer treatment. ICIs are able to block the tumor from attacking T cells 
from the checkpoint proteins [3,4]. 
 
The immune system is critical in the fight against cancer. The immune system consists of many 
cells to fight off threats. Macrophages are cells that have flexible tendrils that they use to snag and attack 
their targets. Dendritic cells give directions to the T-cells and B-cells to where their targets are. NK cells 
are rapid response cells that attack viruses and are aggressive in attacking cancerous and precancerous 
cells. The B-cells create antibodies that help fight off viruses and bacteria while the T-cells are divided 
into helper T-cells that stimulate the B-cells intro producing antibodies and killer T-cells that attack 
harmful cells directly. There is a fine balance between the cell mutation burden and the effectiveness of 
the immune system. When the immune system is overwhelmed by the tumor, it fails to respond to the 
threat. The tipping point is thought to be when the cancer cell recruits immune cells to aid the cancer 
cells growth and travel [5]. 
 
 Immunotherapy drugs allow the immune system to work harder making it eliminate cancer 
cells. ICIs are different compared to conventional therapies such as radiotherapy and chemotherapy as it 
activates the immune system to kill the cancer cells. Immunotherapy offers many benefits that other 
treatments can not offer [6]. The immune system has memory, which can be used to go after cancer cells 
if it does come back. It is proven to help other treatments work better, and also causes fewer side effects 
because it targets only the immune system and not all the cells in your body [7-9]. The risks include bad 
reactions to the medications, not working for every individual and the start-up of the immune system, 
making you feel like you have the flu [10,11]. 
 
Immune checkpoint inhibitors first started when a clinical trial consisting of patients with 
unresectable stage III/IV melanoma, demonstrated improved survival after receiving treatment with a 
fully human IgG1κ anti-CTLA-4 monoclonal antibody [12]. This study allowed for the FDA approval of 
ipilimumab, the first immune checkpoint inhibitor approved for cancer therapy, in 2011. Since 2011 
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there have been 6 ICIs approved for numerous cancer indications that target CTLA-4 PD-1 and PD-L1 
have had unparalleled and lasting responses in a majority of cancer patients in recent years [13]. It is also 
noteworthy that ICIs take a shorter duration of time to be approved by the FDA compared to other 
anticancer agents. This allows ICIs to benefit from access to FDA programs for accelerated development 
[14]. 
 
PD-1 and PD-L1 inhibitors are a group of checkpoint inhibitors, currently being developed for 
cancer treatment. PD-1 and PD-L1 are proteins found on the surface of cells and the interaction of the 
two proteins causes the suppression of the immune system or prevention of autoimmune disease. Over 
the years, patient eligibility for immune checkpoint inhibitors has increased from 1.54% to 43.63% 
while patient response rates have also skyrocketed from 0.14% to 12.46% from 2011 to 2018 [15]. Even 
though ICI have revolutionized cancer treatment due to their durable remissions in many patients who 
have failed prior treatment and effectiveness against a large number of cancers, it does not work for 
everyone [16].The patient responses to ICI vary tremendously such as melanoma having a much higher 
response rate when compared to prostate cancer [17]. Combination therapy is a new trend in the field of 
immunology because it can increase efficacy [18-20]. As mentioned prior, not all patients benefit from 
single-agent ICI therapy, which prompts the idea of combination therapy improving patient response 
outcomes [21-24]. Ideally, the combination of drugs should complement the mechanisms of each drug to 
maximize benefit and minimize toxicity [25-27]. 
Programmed cell death protein 1 (PD-1) 
Biology of PD-1  
In the year 1992, Tasuko Honjo, Yasumasa Ishida and colleagues at Kyoto University, were 
performing screenings of genes involved in apoptosis, when they discovered and named PD-1 (also 
known as CD279) [28]. Seven years later, the same team established that when PD-1 was knocked out of 
a mouse, they were prone to autoimmune disease and thus determined PD-1 was a negative regulator of 
immune responses [29]. 
 
PD-1 is expressed on a vast scale of immune cells, such as monocytes, T cells, B cells, dendritic 
cells and tumor-infiltrating lymphocytes(TILs). RNA is expressed on almost all human tissues and 
particularly, the appendix, bone marrow, lymph nodes, tonsils, spleen ,and small intestine are expressed 
in greater quantities [30,31]. 
 
PD-1 is a protein on the cell’s surface that suppresses both the immune system’s response to 
human cells and the T-cell’s inflammatory activity, by bolstering the body’s ability to tolerate foreign 
cells. This process prevents autoimmune diseases, but also prevents the immune system from 
recognizing and killing cancer cells [32]. It is able to prevent autoimmunity through two mechanisms. 
First, in lymph nodes, PD-1 promotes apoptosis of antigen-specific T cells and second, it lessons 
apoptosis in regulatory T-cells [33,34].  
 
PD-1 is a type 1 membrane protein, which contains 268 amino acids and is a member of the T 
cell regulator family [28]. The protein’s arrangement comprises an extracellular IgV domain, a 
transmembrane region, and an intracellular tail. Located in an immunoreceptor tyrosine-based 
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inhibitory motif and immunoreceptor tyrosine-based switch motif, the intracellular tail contains two 
phosphorylation sites which suggest that PD-1 suppresses the T-cell receptor(TCR) signals. 
Furthermore, PD-1 ligation stimulates E3-ubiquitin ligases CBL-b and c-CBL that sparks TCR 
down-modulation. Since PD-1 is expressed on the surface of activated T cells, B cells, and macrophages, 
it suggests PD-1 provides a broader suppression of immune response than CTLA-4 [35]. 
 
PD-1 is an immune checkpoint that allows the T cell to check for foreign cells, but is rendered 
useless when bound with the tumor cell’s PD-L1. When a cancer cell detects high levels of 
interferon-gamma, an expression of PD-L1 will be induced. Then when a CD8+ T cell checks the cancer 
cell, the CD8+ T cell’s PD-1 will bind with PD-L1, causing the exhaustion of the CD8+ T cell, reducing 
the secretion of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-2 
(IL-2) and interferon-gamma (IFN-γ), unlike the active CD8+ T cell, which secretes TNF-α, IL-2 and 
IFN-γ to kill the mutated cell. Contrarily, when there is either an upregulation of PI3K-Akt kinases or 
secretion of IFN-γ, it causes more expression of PD-L1, in which two general types of immune 
resistance is created, specifically, innate immune resistance, and adaptive immune resistance [36].  
 
PD-1 inhibitor drugs 
Merck, a pharmaceutical company based in New Jersey, developed a drug called 
Keytruda(pembrolizumab) which has been FDA approved for applications of melanoma, advanced 
non-small cell lung cancer, head and neck squamous cell cancer, advanced urothelial bladder cancer, 
classical Hodgkin lymphoma, advanced gastric cancer, advanced Merkel cell carcinoma, advanced 
cervical cancer, advanced hepatocellular carcinoma, primary mediastinal B-cell lymphoma and 
advanced kidney cancer, which have been approved between 2014 and 2019. Overall the response rate 
for those cancer’s ranges from 13.3% for advanced gastric cancer to 69% of classical Hodgkin 
lymphoma (Table 1).  
 
Lung cancer is the leading cause of cancer death among both men and women, which has 
228,150 diagnosed each year and a 5-year survival rate of 19%. NSCLC(Non-Small Cell Lung Cancer), 
a form of epithelial lung cancer accounts for roughly 84% of the lung cancer population [1]. Recently 
Merck has produced a drug called Keytruda, which was approved by the FDA in 2015 to reduce the 
number of deaths and increase the survival rate of the patients diagnosed with advanced NSCLC [37]. 
So far, the treatments for early NSCLC is surgery sometimes with chemotherapy, but for advanced 
NSCLC it is treated with chemotherapy, targeted drugs or immunotherapy [38]. According to the 
clinical trial results, with 410 participants for the Keytruda and chemotherapy study and 206 for the 
chemotherapy study, the median survival rate for Keytruda combination therapy with chemotherapy was 
8.8 months compared to chemotherapy alone of 4.9 months, patient’s partial response was 47% and full 
response was 0.5% when combined with chemotherapy (Table 1).  
  
As of June 2019, Keytruda was approved for the usage of small cell lung cancer, which accounts 
for 10% to 15% of all lung cancers. The disease is commonly attributed to smoking and develops in the 
bronchi. According to keynote 158, which composed of 83 total patients, all received Keytruda 
monotherapy after failed previous treatments, had an overall response rate of 19%, 17% of which were 
partial and 2% were full responses [39-41].  
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Kidney cancer, also called renal cell carcinoma, is a urinary disease that is estimated to have 
73,820 new cases, 14,770 deaths in 2019 and a 5-year survival rate of 75% [42]. The conventional 
treatments for kidney cancer were either surgery or ablation therapy, which uses extreme temperature to 
destroy the tumor cells, but in 2019 the FDA approved Keytruda for the usage of advanced kidney 
cancer, which has increased the patient response rate [1]. As shown by Keytruda’s clinical trials, there is 
a median survival rate of 15 months when combined with chemotherapy, 4 months more than 
chemotherapy alone, and a 59% response rate which has a 53% partial response and a 6% full response 
rate for a clinical study that involved 432 participants using Keytruda combined with chemotherapy and 
429 using chemotherapy alone [43]. 
 
Opdivo(Nivolumab), developed by Bristol-Myers Squibb(BMS) was among the first immune 
checkpoint inhibitors(ICIs) to hit the PD-1 market. From 2014 to 2018, the FDA has approved multiple 
usages of this drug for several cancer indications. Those cancer indications are melanoma, NSCLC, 
advanced kidney cancer, advanced bladder cancer, advanced liver cancer ,and small cell lung cancer. 
The patient response rates to these cancers range from 11% for small cell lung cancer to 50% for 
melanoma (Table 1). 
 
The most dangerous form of skin cancer, melanoma develops in the cells that produce melanin 
and can form in your eyes and in rare cases in internal organs. Melanoma is estimated to have 96,480 
new cases in 2019 and about 7000 people are expected to die of this disease [44]. As Opdivo’s first FDA 
approval for cancer treatment, it is used most effectively when combined with Yervoy having a 50% 
response rate which is a 33% partial response and a 17% full response with the study containing 314 
participants as shown by the Checkmate-067 study. Currently, the treatments available for melanoma are 
surgery, immunotherapy, chemotherapy, radiation therapy and BRAF targeted therapy, which is able to 
slow down the growth of melanoma, but later on, the tumor cell develops resistance to the drug allowing 
for a relapse. On the other hand, ICIs develop memory that allow it to prevent the relapse of melanoma 
[45]. 
 
Bladder cancer, which will have 80,470 new cases and 17,670 deaths in 2019 [46]. This form of 
cancer occurs when bladder cells become abnormal, which can spread to nearby lymph nodes, organs 
and in severe cases, can spread to the bones, lungs ,and liver. Smoking is the most established risk factor 
of bladder cancer contributing to 47% of the cases and bladder cancer as a whole has a high tumor 
mutation burden, which can potentially have a higher patient response rate for immunotherapy. Opdivo 
was approved by the FDA in 2017 and during the Checkmate-275 study, the response rate of patients 
who failed prior treatment was 19.6%, composed of 17% partial and 2.6 full response rate found from a 
study containing 270 participants (Table 1). 
Programmed death-ligand 1 (PD-L1) 
Biology of PD-L1 
Programmed death-ligand 1(PD-L1 or B7H1) is a protein present in humans that is encoded by 
the CD274 gene. It was first characterized by the Mayo Clinic as an immune regulatory molecule B7H1. 
Later on, this molecule was renamed PD-L1 as it was identified as a ligand to PD-1 [47]. It is expressed 
in multiple human tissues like the lung, placenta, lymph nodes and spleen [31,48]. There are several 
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human cancer cells such as thyroid, urothelial and lung cancers that express high levels of PD-L1 [30]. 
PD-L1 was then shown to be expressed on Myeloid cells as a checkpoint protein and was suggested as a 
potential target in cancer immunotherapy [49]. 
 
PD-L1 is a type 1 transmembrane glycoprotein composed of both IgC- and IgV- type 
extracurricular domains [50]. It is believed to have a major role in the suppression of the acquired 
immune system during certain events such as autoimmune disease. The binding between PD-L1 and 
PD-1 transmits a suppressive signal based on interaction with phosphatases through Immunoreceptor 
Tyrosine-Based Switch Motif (ITSM) [51]. This signal reduces the buildup of antigen-specific T-cells in 
regulatory T cells, which is mediated by a lower regulation of the gene Bcl-2. 
 
PD-L1 expressed is induced in cancer response over-express of cytokines like INF-γ, and 
TNF-α. In 2003, Curiel et.al showed that a blockade of PD-L1 led to a reduction to the growth of tumors 
in the presence of immune cells, and it was then concluded that PD-L1 helps tumor cells evade 
anti-tumor immunity. When bound together with its receptor PD-1, PD-L1 is able to neutralize the 
T-cell’s activating signals. Expression of PD-L1 on tumor cells in the tumor microenvironment is of 
major clinical applicability, due to the fact that antibody-based PD-1 and PD-L1 inhibitors can activate 
durable tumor remissions in patients with various advanced cancers [49]. 
 
PD-L1 inhibitor drugs 
Tecentriq(Atezolimub) was developed by Roche(Genentech), a Swiss multinational healthcare 
company is a new drug on the PD-L1 market. From 2016 to 2019, there have been 4 FDA approvals for 
the usage of advanced bladder cancer, metastatic non-small cell lung cancer, extensive stage small cell 
lung cancer, and metastatic triple negative breast cancer. The patient response rates range from 23.5% 
for advanced bladder cancer to 53% for TNBC (Table 1). 
 
Triple Negative Breast Cancer, a form of breast cancer that accounts for 10 - 20% of all breast 
cancers, occurs when the three most common receptors that fuel breast cancer growth, estrogen, 
progesterone, and HER-2 are not present in the tumor [52]. Due to the tumors lack of necessary 
receptors, common treatments such as hormone therapy and drugs that specifically target estrogen, 
progesterone and HER-2 are ineffective. Compared with hormone receptor-positive breast cancers, 
triple negative breast cancer has a worse patient outcome and an aggressive history. In 2019, 
Tecentriq(Atezolizumab) was approved by the FD for patients with Triple Negative Breast Cancer. In a 
clinical study of 902 total participants, patients that received Tecentriq and Chemotherapy had a median 
survival rate of 21.3 months, while patients that received placebo and chemotherapy had a median 
survival rate of 17.6 months. The objective response rate of the patients was 53% for the Tecentriq group 
and 33% for the placebo group (Table 1).  
 
Extensive stage small cell lung cancer is a form of lung cancer that does not fit into the criteria 
set by the International Association for the Study of Lung Cancer “disease restricted to one hemithorax 
with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and 
ipsilateral and contralateral supraclavicular nodes and should also include patients with ipsilateral 
pleural effusion independent of whether cytology is positive or negative” [53]. The disease accounts for 
60% to 70% of all small cell lung cancer cases at the time of diagnosis [54]. Tecentriq’s usage for 
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extensive stage small cell lung cancer was not FDA approved until 2019. Roche’s clinical study of 403 
total patients, showed that when Tecentriq is combined with chemotherapy, the median survival rate is 
12.3 is months, but when the patient receives only chemotherapy the median survival rate is 10.3 months 
(Table 1). 
 
In 2018, AstraZeneca’s drug Imfinzi, a PD-L1 inhibitor was FDA approved allowing for the 
treatment of NSCLC. In their clinical trial of 476 patients on Imfinzi and 237 on placebo, the median 
survival rate was not reached and there was a 95% CI of (34.7, NR). On the other hand, the placebo 
group’s median survival rate was 28.7 months and a 95% CI of (22.9, NR) (Table 1). 
 
Merkel cells are found in the basal epidermal layer of the skin. Merkel cell carcinoma or 
neuroendocrine carcinoma is a rare form of skin cancer that forms in areas of skin commonly exposed to 
the sun [55]. Bavencio developed by Pfizer was FDA approved for the usage of metastatic Merkel cell 
carcinoma in 2017. Through a clinical study of 88 patients receiving Bavencio combined with 
chemotherapy, there was a 33% response rate, 22% of which were partial response and 11% were full 
responses (Table 1).  
Summary 
Since nivolumab’s clinical trial in 2006, there have been 6 new monoclonal antibodies(mAbs) 
targeting PD-1 and its ligand PD-L1 approved by the FDA to treat 14 different cancer indications. 
Furthermore, there has been a dramatic surge of active clinical trials testing anti PD-1 and PD-L1 agents, 
starting with 1 in 2006 and 2,250 as of September 2018. Of the 2,250 active trials, 1,716 are trials testing 
combination therapy. Though combination therapy only has two FDA approvals, there are 240 different 
targets that can be assessed anti PD-1 and PD-L1 agents. With so many clinical trials active, the need for 
patient volunteers has increased greatly. These trials have recruited patients at a rate of 1.15 patients per 
site per month in 2014 ad is now slowing down to 0.35 patients per site per month in 2018. This suggests 
that combination therapy trials will face difficulty in their recruitment process in the near future for 
certain cancer types. Patient response rates have also been on the rise, such as the usage of Keytruda for 
Hodgkin lymphoma reaching a 69% patient response rate and Opdivo used with Yervoy for melanoma 
reaching a 50% patient response rate. But not all indications of cancer have a high patient response rate 
like gastric cancer where the response rate is only 13.3%. These statistics show that the fight against 
cancer is nowhere near finished [56]. New combination therapies or ICIs may potentially help increase 
patient response rates [57-60]. 
 
Given only a subset of patients deriving clinical benefit, it is crucial to understand and define a 
group of biomarkers, which is predictive of patient response and resistance [61-63]. So far many 
biomarkers have been discovered such as tumor mutation burden(TMB) [64,65], PDL1 expression, 
DNA mismatch repair deficiency [66], gut microbial diversity [67], HLA class genotype [68], and T 
cell-inflamed microenvironment [69]. TMB can affect the development of immunogenic peptides, thus 
affecting the ICI response in patients [70]. The best initial ICI response rates were found in cancers such 
as melanoma and NSCLC, which typically has a high TMB, owing to the mutagenic effects of 
ultraviolet light and cigarette smoke. In two melanoma studies, patients who had, on average a higher 
pre-therapy TMB than others, tended to experience durable clinical benefit from ipilimumab [71]. A 
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second study of melanoma patients only establishes an association between a high TMB and response to 
ipilimumab that patients with a TMB greater than 100 had a statistically higher overall survival (OS) 
percentage [72,73]. There have already been many biomarkers discovered [74], but more biomarkers are 
needed to improve patient response rates [75-78]. Patient response rates can also be improved through 
the discovery of an effective combination of biomarkers. Beside PD-1 and PD-L1, new ICIs targeting 
new targets such as Siglec-15 are under development [79].  
 
Despite approvals of PD-1 and PD-L1 drugs in the United States and Europe, China is 
developing its own drugs towards these targets. In China, immuno-oncology remains at a preliminary 
stage. Although there are 26 active phase I studies investigating 14 ICIs, early phase designs 
incorporating the characteristics of Chinese patients are lackluster. Currently, there are 15 companies 
developing new ICIs in China. As of June 1, 2018, there has not been an ICI approved by the CFDA. 
Besides ICIs, there are several other fields of immunotherapy currently being developed such as T-cell 
therapy and cancer vaccines [80-82]. In the field of immuno-oncology, ICIs are a breakthrough in cancer 
treatment that shows extreme promise. 
 
Table 1. Immune checkpoint inhibitors approved by the US FDA 
Drugs 
FDA approved  
Indications 
Patient  
number 
MedianOS 
(month) 
Patient  
Response Rate 
Year Reference 
Keytruda 
Pembrolizumab 
Melanoma 277 4.1  33%(27%;6%)* 2014 [83] 
Advanced NSCLC 410 8.8 48%(47%;0.5%) ** 2015 [84] 
Advanced Bladder Cancer 270 2.1 29%(22%;7%)* 2017  [85] 
Hodgkin Lymphoma 210 n/a 69%(47%;22%)** 2017 [86] 
PMBCL 53 31.4 45%(34%;11%)** 2018 [87] 
Advanced Kidney Cancer 432 15 59%(53%;6%) ** 2019 [43] 
Advanced Gastric Cancer 143 n/a 13.3%(11.9%;1.4%) ** 2017 [88] 
Advanced Liver Cancer  104 12.9 17%(16%;1%) * 2018 [89] 
HNSCC 174 n/a 16%(11%;5%)* 2016 [90] 
Advanced Cervical Cancer 77 9.4 14.3%(11.7%;2.6%) ** 2018 [40] 
Advanced MCC 50 16.8a   56%(32%;24%)* 2018 [91] 
Advanced SCLC 83 n/a 19%(17%;2%)* 2019 [40] 
Opdivo Melanoma 314      11.1a 50%(33%;17%) ** 2014 [92] 
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Nivolumab NSCLC 135 9.2 19%** 2015 [93] 
SCLC 109 5.6 11%(10%;0.9%)** 2018 [92] 
Advanced Liver Cancer 154 NR 14.3%(12.3%;2%)** 2017 [94] 
RCC 425 NR 41.6%(32.2%;9.4%)** 2015 [95] 
Colorectal Cancer dMMR 82 n/a 46%(43%;3.7%)** 2018 [96] 
Advanced Bladder Cancer 270 8.74 19.6%(17%;2.6%)** 2017 [97] 
Tecentriq 
Atezolizumab 
Metastatic NSCLC 850 13.8 n/a 2018 [98] 
Extensive Stage SCLC 403 12.3 n/a 2019 [99] 
Metastatic TNBC 902 21.3 53%* 2019 [100] 
Advanced Bladder Cancer 119 5.9 23.5%* 2016 [101] 
Imfinzi 
Durvalumab 
Unresectable  
Stage 3 NSCLC 
476 34.7NR n/a 2018 [102] 
Metastatic UC 191 18.2 17%(14.3%;2.7%)** 2017 [103] 
Bavencio 
Avelumab 
 
RCC 886 13.8 51.4%** 2019 [104] 
Metastatic UC 161 6.5 16.1%(10.6%;5.6%)** 2017 [105] 
Metastatic MCC 88  n/a 33%(22%;11%)** 2017 [106] 
 
*  = monotherapy,  
** = combined therapy 
a = PFS and MedianOS-NR 
PMBCL = Primary Mediastinal B-Cell Lymphoma,  
HNSCC = Head and Neck Squamous Cell Cancer, 
TNBC = Triple Negative Breast Cancer,  
UC = Urethral Carcinoma,  
MCC = Merkel Cell Carcinoma 
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Figure 1. FDA approval years for ICI product in different indications 
 
Acknowledgement 
I wish to thank Dr. Xue Gong for her continuous guidance and support in the development of this review. 
Reference 
1.  Society AC. Cancer facts & figures. 2019 
2.  https://www.cancer.net/navigating-cancer-care/cancer-basics/what-cancer 
3.  https://www.raconteur.net/healthcare/history-of-cancer-treatment 
4.  Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018, 
359:1350-1355 
5.https://www.cancercenter.com/community/blog/2017/10/how-does-the-immune-system-work-when-i
t-comes-to-cancer-its-complicated  
6.  Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH. Immunotherapy in colorectal 
cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019,16:361-375 
7.  Delanoy N, Michot J-M, Comont T, Kramkimel N, Lazarovici J, Dupont R. Haematological 
immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive 
observational study. Lancet Haematol. 2019,6:e48-57 
8.  Khan Z, Hammer C, Guardino E, Chandler GS, Albert ML. Mechanisms of immune-related adverse 
events associated with immune checkpoint blockade: using germline genetics to develop a 
personalized approach. Genome Med. 2019, 20;11:39 
9.  Spain L, Walls G, Julve M, O’Meara K, Schmid T, Kalaitzaki E. Neurotoxicity from 
immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review 
of the literature. Ann Oncol. 2017, 28:377-385 
10.  Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV. Myositis and neuromuscular 
side-effects induced by immune checkpoint inhibitors. Eur J Cancer. 2019, 106:12-23 
11.  https://www.webmd.com/cancer/immunotherapy-risks-benefits#1 
12.  Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB. Improved survival with 
ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363:711-723 
  
 
Ivy Union Publishing | http: //www.ivyunion.org            ISSN 2572-5750          August 13, 2019 | Volume 7 | Issue 1 
Zhang H. American Journals of Cancer Science 2019, 7:18-31                                 Page 11 of 14 
 
13.  Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An 
overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018, 
62:29-39 
14.  Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R. 
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory 
advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014, 
384:1109-1117 
15.  Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for 
and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019, 2:e192535 
16.  Carretero-González A, Lora D, Ghanem I, Zugazagoitia J, Castellano D, Sepúlveda JM. Analysis of 
response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a 
meta-analysis of randomized clinical trials. Oncotarget. 2018, 9:8706-8715 
17.  Poggio M, Hu T, Pai C-C, Chu B, Belair CD, Chang A. Suppression of Exosomal PD-L1 Induces 
Systemic Anti-tumor Immunity and Memory. Cell. 2019, 177:414-427 
18.  Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and targeted therapy 
combinations in metastatic breast cancer. Lancet Oncol. 2019, 20:e175-186 
19.  Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V. Prophylactic TNF blockade 
uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019, 
569:428-432 
20.  Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH, Carlino MS. Combined BRAF and MEK 
inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med. 2019, 
25:936-940 
21.  Rivera Vargas T, Apetoh L. Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to 
Immune Checkpoint Inhibitors? Front Immunol. 2019, 10:1181 
22.  Muto Y, Kitano S. [Clinical Significance of Ipilimumab and the Combination Therapy as Immune 
Checkpoint Inhibitor]. Gan To Kagaku Ryoho. 2019, 46:1011-1015 
23.  https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.8_suppl.TPS25 
24.  https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e14103 
25.  Wu Y, Shi H, Jiang M, Qiu M, Jia K, Cao T. The clinical value of combination of immune 
checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety. Int J Cancer. 2017, 
141:2562-2570 
26.  Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing antitumor 
response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann 
Oncol. 2019, 30:219-235 
27.  Melosky B, Juergens R, Hirsh V, McLeod D, Leighl N, Tsao M-S. Amplifying Outcomes: 
Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. Oncologist. 2019, 
28 
28.  Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the 
immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992, 11:3887-3895. 
29.  Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 Pathway from Discovery to Clinical 
Implementation. Front Immunol. 2016, 7:550 
30.  Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G. A pathology atlas of the human 
cancer transcriptome. Science. 2017, 18:357 
31.  Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M. Towards a 
knowledge-based Human Protein Atlas. Nat Biotechnol. 2010, 28:1248-1250 
32.  Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint 
targeting. Lancet Oncol. 2017, 18:e731-741 
33.  Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol 
Rev. 2010, 236:219-422 
34.  Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann 
N Y Acad Sci. 2011, 1217:45-59 
35.  Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL, Collins M. PD-L1 co-stimulation 
contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med. 
2011, 3:581-592 
  
 
Ivy Union Publishing | http: //www.ivyunion.org            ISSN 2572-5750          August 13, 2019 | Volume 7 | Issue 1 
Zhang H. American Journals of Cancer Science 2019, 7:18-31                                 Page 12 of 14 
 
36.  Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer 
immunotherapy. Nat Rev Immunol. 2018, 18:545-558 
37.  http://atm.amegroups.com/article/view/27166 
38.  http://jtd.amegroups.com/article/view/30170 
39.https://www.healio.com/hematology-oncology/lung-cancer/news/online/%7B9ed41cd1-4387-4662-
94c2-3b8389080633%7D/fda-approves-keytruda-for-metastatic-small-cell-lung-cancer 
40.  Chung HC, Ros W, Delord J-P, Perets R, Italiano A, Shapira-Frommer R. Efficacy and Safety of 
Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II 
KEYNOTE-158 Study. J Clin Oncol. 2019, 37:1470-1478 
41.  Rossi A. Immunotherapy in small-cell lung cancer: at what point are we? Ann Transl Med. 2016, 
4(Suppl 1):S5 
42.  https://www.cancer.org/cancer/kidney-cancer/about/key-statistics.html. 
43.  https://www.keytruda.com/advanced-kidney-cancer/combination-therapy-clinical-trial-results/ 
44.  https://www.curemelanoma.org/about-melanoma/melanoma-statistics-2/ 
45.  https://www.curemelanoma.org/blog/article/overcoming-targeted-therapy-resistance 
46.  https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html 
47.  Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell 
proliferation and interleukin-10 secretion. Nat Med. 1999, 5:1365-1369 
48.  Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A. Proteomics. 
Tissue-based map of the human proteome. Science. 2015, 347:1260419 
49.  Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P. Blockade of B7-H1 improves myeloid 
dendritic cell-mediated antitumor immunity. Nat Med. 2003, 9:562-567 
50.  Freeman GJ. Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. Proc Natl 
Acad Sci USA. 2008, 105:10275-10276 
51.  Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with 
immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell 
stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004, 173:945-954 
52.  Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of 
triple-negative breast cancer. Curr Oncol. 2018, 25(Suppl 1):S142-150 
53.  Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K. The International 
Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the 
clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, 
metastasis classification for lung cancer. J Thorac Oncol. 2007, 2:1067-1077 
54.  https://www.verywellhealth.com/extensive-stage-small-cell-lung-cancer-2249370. 
55.  https://www.dana-farber.org/merkel-cell-carcinoma/ 
56.  Tang J, Yu JX, Hubbard-Lucey VM, Neftelinov ST, Hodge JP, Lin Y. Trial watch: The clinical trial 
landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov. 2018, 17:854-855. 
57.  Zappasodi R, Sirard C, Li Y, Budhu S, Abu-Akeel M, Liu C. Rational design of anti-GITR-based 
combination immunotherapy. Nat Med. 2019, 25:759-766 
58.  http://cancerres.aacrjournals.org/content/79/13_Supplement/1086.short 
59.  Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing 
outcomes in melanoma. Nat Rev Clin Oncol. 2017, 14:463-482 
60.  Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer 
immunotherapy. Nat Rev Immunol. 2018, 18:498-513 
61.  Greally M, Chou JF, Chatila WK, Margolis M, Capanu M, Hechtman JF. Clinical and molecular 
predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric 
cancer. Clin Cancer Res. 2019, 23 
62.  https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e14138 
63.  Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor 
immunotherapy. Nat Rev Cancer. 2019, 19:133-150 
64.  Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T. Immune and genomic correlates 
of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019, 25:462-469 
65.  Samstein RM, Lee C-H, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY. Tumor mutational 
load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019, 
  
 
Ivy Union Publishing | http: //www.ivyunion.org            ISSN 2572-5750          August 13, 2019 | Volume 7 | Issue 1 
Zhang H. American Journals of Cancer Science 2019, 7:18-31                                 Page 13 of 14 
 
51:202-206 
66.  Mandal R, Samstein RM, Lee K-W, Havel JJ, Wang H, Krishna C. Genetic diversity of tumors with 
mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science. 2019, 
364:485-491 
67.  Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R. Gut microbiome influences 
efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018, 359:91-97 
68.  Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V. Patient HLA class I 
genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018, 
359:582-587 
69.  Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW. Defining T Cell States 
Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2019, 176:404. 
70.  https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.2578 
71.  Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A. Genetic basis for clinical 
response to CTLA-4 blockade in melanoma. N Engl J Med. 2014, 371:2189-2199 
72.  Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ. Cancer immunology 
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. 
Science. 2015, 348:124-128 
73.  Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L. Genomic correlates of 
response to CTLA-4 blockade in metastatic melanoma. Science. 2015, 350:207-211 
74.  Lambertini M, Preusser M, Zielinski CC. New emerging targets in cancer immunotherapy beyond 
CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open - Cancer Horizons” Series. ESMO Open. 
2019, 4(Suppl 3):e000501 
75.  http://cancerres.aacrjournals.org/content/79/13_Supplement/3224.short 
76.  http://cancerres.aacrjournals.org/content/79/13_Supplement/2230.short 
77.  http://cancerres.aacrjournals.org/content/79/13_Supplement/2250.short 
78.  https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e15679 
79.  Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M. Siglec-15 as an immune suppressor and potential 
target for normalization cancer immunotherapy. Nat Med. 2019, 25:656-666 
80.  Fang W, Zhao S, Zhang Y, Ma Y, Zhao H, Zhang L. Ongoing Phase I Studies of Immune Checkpoint 
Inhibitors in China. Oncologist. 2019, 24:S11-20 
81.  Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018, 
359:1355-1360.82.  Depil S, Bonaventura P, Alcazer V. Cancer vaccines: what’s next? 
Oncotarget. 2019, 10:3985-3987. 
83.  https://www.keytruda.com/melanoma/keytruda-clinical-trials/ 
84.  https://www.keytruda.com/non-small-cell-lung-cancer/combination-therapy-clinical-trial-results/ 
85.  https://www.keytruda.com/advanced-urothelial-bladder-cancer/previously-treated-clinical-trials/ 
86.  Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P. Phase II Study of the Efficacy 
and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 
2017, 35:2125-2132 
87.  http://www.bloodjournal.org/content/132/Suppl_1/228?sso-checked=true 
88.  Bang Y-J, Kang Y-K, Catenacci DV, Muro K, Fuchs CS, Geva R. Pembrolizumab alone or in 
combination with chemotherapy as first-line therapy for patients with advanced gastric or 
gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized 
KEYNOTE-059 study. Gastric Cancer. 2019, 22:828-837 
89.  Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D. Pembrolizumab in patients with 
advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a 
non-randomised, open-label phase 2 trial. Lancet Oncol. 2018, 19:940-952 
90.  Larkins E, Blumenthal GM, Yuan W, He K, Sridhara R, Subramaniam S. FDA Approval Summary: 
Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell 
Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy. Oncologist. 
2017, 22:873-878 
91.  Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS. Durable Tumor 
Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving 
Pembrolizumab as First-Line Therapy. J Clin Oncol. 2019, 37:693-702 
  
 
Ivy Union Publishing | http: //www.ivyunion.org            ISSN 2572-5750          August 13, 2019 | Volume 7 | Issue 1 
Zhang H. American Journals of Cancer Science 2019, 7:18-31                                 Page 14 of 14 
 
92.  Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Cowey CL. Nivolumab plus 
ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 
4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018, 19:1480-1492. 
93.  https://www.opdivo.com/advanced-nsclc/about-opdivo/clinical-trial-results  
94.  El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C. Nivolumab in patients with 
advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 
dose escalation and expansion trial. Lancet. 2017, 389:2492-2502 
95.  Cella D, Grünwald V, Escudier B, Hammers HJ, George S, Nathan P. Patient-reported outcomes of 
patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus 
sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 2019, 20:297-310 
96.  Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ. Treatment Beyond 
Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in 
CheckMate 025. Eur Urol. 2017, 72:368-376 
97.  Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J. Nivolumab in metastatic 
urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 
trial. Lancet Oncol. 2017, 18:312-322 
98.  Atezolizumab for non-small cell lung cancer. Aust Prescr. 2018, 41:124 
99.  Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung 
carcinoma: current status and future prospects. Eur Respir J. 2010, 35:202-215 
100.https://www.cancer.gov/news-events/cancer-currents-blog/2019/atezolizumab-triple-negative-brea
st-cancer-fda-approval.  
101. Bernard-Tessier A, Bonnet C, Lavaud P, Gizzi M, Loriot Y, Massard C. [Atezolizumab 
(Tecentriq®): Activity, indication and modality of use in advanced or metastatic urinary bladder 
carcinoma]. Bull Cancer. 2018, 105:140-145 
102.https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-is-the-first-immunotherap
y-to-demonstrate-significant-overall-survival-benefit-in-unresectable-stage-iii-lung-cancer250920
18.htm 
103. Powles T, O’Donnell PH, Massard C, Arkenau H-T, Friedlander TW, Hoimes CJ. Efficacy and 
Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results 
From a Phase 1/2 Open-label Study. JAMA Oncol. 2017, 3:e172411 
104.https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_bavencio_avelumab
_plus_inlyta_axitinib_combination_for_patients_with_advanced_renal_cell_carcinoma 
105. Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R. Avelumab in metastatic 
urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two 
expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018, 19:51-64 
106. Cordes LM, Gulley JL. Avelumab for the treatment of metastatic Merkel cell carcinoma. Drugs 
Today. 2017, 53:377-383 
 
